Last reviewed · How we verify
Furaxolon (NIDROXYZONE)
Furaxolon (generic name: NIDROXYZONE) is a drug. It is currently in Phase 2 development.
Furaxolon works by binding to specific proteins or receptors in the body to produce a therapeutic effect.
Furaxolon, also known as NIDROXYZONE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. The approved indications for Furaxolon are also unknown. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further research is needed to fully understand its mechanism of action and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NIDROXYZONE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine Furaxolon as a key that fits into a specific lock in the body. When it binds to that lock, it can turn on or off certain cellular processes, which can help to treat a particular disease or condition. This is a simplified explanation of how Furaxolon works at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Furaxolon CI brief — competitive landscape report
- Furaxolon updates RSS · CI watch RSS
Frequently asked questions about Furaxolon
What is Furaxolon?
How does Furaxolon work?
What is the generic name of Furaxolon?
What development phase is Furaxolon in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing